Trabectedin
- Generic Name
- Trabectedin
- Brand Names
- Yondelis
- Drug Type
- Small Molecule
- Chemical Formula
- C39H43N3O11S
- CAS Number
- 114899-77-3
- Unique Ingredient Identifier
- ID0YZQ2TCP
- Background
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate Ecteinascidia turbinata and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machin...
- Indication
用于治疗急性淋巴母细胞白血病、晚期软组织肉瘤及复发卵巢癌。
- Associated Conditions
- Metastatic Leiomyosarcoma, Metastatic Liposarcoma, Platinum Sensitive Relapsed Ovarian Cancer, Unresectable Leiomyosarcoma, Unresectable Liposarcoma
- Associated Therapies
- -
Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2017-03-08
- Last Posted Date
- 2022-04-29
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT03074318
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Study With Trabectedin Versus Adriamycin Plus Dacarbazine, in Patients With Advanced Solitary Fibrous Tumor
- Conditions
- Interventions
- First Posted Date
- 2017-01-18
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Italian Sarcoma Group
- Target Recruit Count
- 23
- Registration Number
- NCT03023124
- Locations
- 🇮🇹
Nuovo Ospedale di Prato, Prato, Firenze, Italy
🇮🇹Policlinico Universitario Campus Biomedico, Roma, RM, Italy
🇮🇹IRCCS Istituto ortopedico Rizzoli, Bologna, Italy
Study Comparing Efficacy of Doxorubicin With Trabectedin Followed by Trabectedin Versus Doxorubicine in Patients With Leiomyosarcoma
- Conditions
- Interventions
- First Posted Date
- 2016-12-20
- Last Posted Date
- 2021-12-30
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 150
- Registration Number
- NCT02997358
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)
- Conditions
- Interventions
- First Posted Date
- 2016-12-15
- Last Posted Date
- 2021-08-25
- Target Recruit Count
- 45
- Registration Number
- NCT02993705
- Locations
- 🇮🇹
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
Trabectedin Maintenance Post 1st-line in STS
- First Posted Date
- 2016-10-11
- Last Posted Date
- 2020-09-02
- Target Recruit Count
- 13
- Registration Number
- NCT02929394
- Locations
- 🇫🇷
Centre Oscar Lambret, Lille, France
🇫🇷Centre Leon Berard, Lyon, France
🇫🇷Institut Bergonie, Bordeaux, France
Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients
- Conditions
- Interventions
- First Posted Date
- 2016-09-16
- Last Posted Date
- 2021-08-25
- Target Recruit Count
- 242
- Registration Number
- NCT02903004
- Locations
- 🇮🇹
Domenica Lorusso, Rome, Italy
Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients
- Conditions
- First Posted Date
- 2016-07-07
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- PharmaMar
- Target Recruit Count
- 220
- Registration Number
- NCT02825420
- Locations
- 🇩🇪
Brustzentrum, Wetzlar, Hesse, Germany
🇮🇹Ospedale S.Maria d. Misericordia, Bergamo, Savona, Italy
🇪🇸Hospital Universitario de La Laguna, San Cristóbal de La Laguna, Santa Cruz De Tenerife, Spain
Retrospective Study of Trabectedin in Soft Tissue Sarcomas
- First Posted Date
- 2016-06-08
- Last Posted Date
- 2019-05-10
- Lead Sponsor
- Italian Sarcoma Group
- Target Recruit Count
- 510
- Registration Number
- NCT02793050
- Locations
- 🇮🇹
Istituto Tumori Giovanni Paolo II, Bari, BA, Italy
🇮🇹Fondazione del Piemonte per l'Oncologia IRCC Candiolo, Candiolo, Torino, Italy
🇮🇹Ospedale Oncologico A. Businco, Cagliari, CA, Italy
Trial Comparing Trabectedin to the Best Supportive Care in Patients With Sarcoma
- First Posted Date
- 2016-02-03
- Last Posted Date
- 2018-08-16
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 103
- Registration Number
- NCT02672527
- Locations
- 🇫🇷
Gustave Roussy Cancer Campus Grand Paris, Villejuif, Val De Marne, France
Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS)
- First Posted Date
- 2015-03-25
- Last Posted Date
- 2021-04-14
- Lead Sponsor
- Italian Sarcoma Group
- Target Recruit Count
- 50
- Registration Number
- NCT02398058
- Locations
- 🇮🇹
Fondazione del Piemonte per l'Oncologia IRCC Candiolo, Candiolo, Torino, Italy
🇮🇹Istituti Ortopedici Rizzoli - Unit of Chemotherapy of Muscoloskeletal Tumors, Bologna, Italy
🇮🇹Istituto Nazionale Tumori - Unit of Medical Oncology, Milano, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.